TP53 and hepatocellular carcinoma: Another study suggested that the sorafenib treatment of HCC cells increases the expression of the pro-apoptotic factor p53-upregulated modulator of apoptosis and activates poly-ADP-ribose polymerase and caspase-3, and that miR-181a induces sorafenib resistance via the suppression of Ras association domain-containing protein 1 [173].